Drug Trial Radar · NCT00622648
Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin
Last checked: Nov 19, 2026Latest source record: Dec 28, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,329
Actual
Start
Jan 2008
Primary completion
Dec 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective: * To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization. The secondary objective: * To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization. * To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .
Conditions
- Acute Illness
Interventions
EnoxaparinDrug
40 mg once daily for 6 to 14 days (10 ± 4 days)
PlaceboDrug
Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Death rate with all causes mortalityTime frame: At day 30
- HemorrhagesTime frame: Occuring until day 90
Locations
9 sites in 9 countries. Site status is shown where the registry gives one.
Sanofi-Aventis Administrative Office
São Paulo, Brazil
Sanofi-Aventis Administrative Office
Shanghai, China
Sanofi-Aventis Administrative Office
Hong Kong, Hong Kong
Sanofi-Aventis Administrative Office
Mumbai, India
Sanofi-Aventis Administrative Office
Kuala Lumpur, Malaysia
Sanofi-Aventis Administrative Office
Col. Coyoacan, Mexico
Sanofi-Aventis Administrative Office
Makati City, Philippines
Sanofi-Aventis Administrative Office
Seoul, South Korea
Sanofi-Aventis Administrative Office
Mégrine, Tunisia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.